Clinical Trial Update: Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CFZ533 in patients with primary Sjögren's syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• CFZ533

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Sjögren's Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-08-14